NASDAQ:MRNS Marinus Pharmaceuticals (MRNS) Stock Price, News & Analysis → Emergency: Biden's $20 Trillion Mistake Could Cost YOU! (From GoldenCrest Metals) (Ad) Free MRNS Stock Alerts $1.44 0.00 (0.00%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$1.39▼$1.4650-Day Range$1.20▼$10.0152-Week Range$1.11▼$11.26Volume1.65 million shsAverage Volume1.47 million shsMarket Capitalization$79.10 millionP/E RatioN/ADividend YieldN/APrice Target$16.07 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Marinus Pharmaceuticals alerts: Email Address Marinus Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.57 Rating ScoreUpside/Downside1,016.1% Upside$16.07 Price TargetShort InterestBearish6.32% of Shares Sold ShortDividend StrengthN/ASustainability-1.55Upright™ Environmental ScoreNews Sentiment0.13Based on 13 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.23) to ($1.14) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.37 out of 5 starsMedical Sector128th out of 909 stocksPharmaceutical Preparations Industry45th out of 423 stocks 4.3 Analyst's Opinion Consensus RatingMarinus Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageMarinus Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.32% of the outstanding shares of Marinus Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverMarinus Pharmaceuticals has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in Marinus Pharmaceuticals has recently decreased by 2.80%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldMarinus Pharmaceuticals does not currently pay a dividend.Dividend GrowthMarinus Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMarinus Pharmaceuticals has received a 60.80% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Epilepsy medication (N03)", "Clinical research services for Epilepsy or seizures", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Marinus Pharmaceuticals is -1.55. Previous Next 2.9 News and Social Media Coverage News SentimentMarinus Pharmaceuticals has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Marinus Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest16 people have searched for MRNS on MarketBeat in the last 30 days. This is an increase of 23% compared to the previous 30 days.MarketBeat Follows71 people have added Marinus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 69% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Marinus Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.46% of the stock of Marinus Pharmaceuticals is held by insiders.Percentage Held by Institutions98.80% of the stock of Marinus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Marinus Pharmaceuticals are expected to grow in the coming year, from ($2.23) to ($1.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Marinus Pharmaceuticals is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Marinus Pharmaceuticals is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMarinus Pharmaceuticals has a P/B Ratio of 4.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad GoldenCrest MetalsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!The stakes have never been higher for your savings. Here's the hard truth: A banking crisis is looming. Your money is in the crosshairs of a $20 trillion commercial loan debt disaster, set to erupt.Learn More Now About Marinus Pharmaceuticals Stock (NASDAQ:MRNS)Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.Read More MRNS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MRNS Stock News HeadlinesApril 24, 2024 | investing.comMarinus Pharmaceuticals Inc (MRNS)April 19, 2024 | americanbankingnews.comFY2024 EPS Estimates for Marinus Pharmaceuticals, Inc. Decreased by Cantor Fitzgerald (NASDAQ:MRNS)April 24, 2024 | GoldenCrest Metals (Ad)Emergency: Biden's $20 Trillion Mistake Could Cost YOU!The stakes have never been higher for your savings. Here's the hard truth: A banking crisis is looming. Your money is in the crosshairs of a $20 trillion commercial loan debt disaster, set to erupt.April 19, 2024 | americanbankingnews.comTruist Financial Lowers Marinus Pharmaceuticals (NASDAQ:MRNS) Price Target to $10.00April 18, 2024 | americanbankingnews.comBrokers Offer Predictions for Marinus Pharmaceuticals, Inc.'s Q1 2024 Earnings (NASDAQ:MRNS)April 17, 2024 | msn.comBaird Downgrades Marinus Pharmaceuticals (MRNS)April 17, 2024 | americanbankingnews.comMarinus Pharmaceuticals (NASDAQ:MRNS) Receives Neutral Rating from Robert W. BairdApril 17, 2024 | americanbankingnews.comMarinus Pharmaceuticals' (MRNS) Buy Rating Reaffirmed at HC WainwrightApril 24, 2024 | GoldenCrest Metals (Ad)Emergency: Biden's $20 Trillion Mistake Could Cost YOU!The stakes have never been higher for your savings. Here's the hard truth: A banking crisis is looming. Your money is in the crosshairs of a $20 trillion commercial loan debt disaster, set to erupt.April 16, 2024 | msn.comRBC Capital Downgrades Marinus Pharmaceuticals (MRNS)April 16, 2024 | americanbankingnews.comMarinus Pharmaceuticals' (MRNS) Sector Perform Rating Reaffirmed at Royal Bank of CanadaApril 15, 2024 | markets.businessinsider.comMaintaining Buy Rating on Marinus Pharmaceuticals: Confidence in Research and Strategic Financial HealthApril 15, 2024 | bizjournals.comMarinus Pharmaceuticals loses 80% of its market value in one day after setback for new drug candidateApril 15, 2024 | investorplace.comBiotech on a Budget: 7 Stocks Under $10 With Huge PotentialApril 15, 2024 | markets.businessinsider.comMarinus Pharmaceuticals, Neumora Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market SessionApril 15, 2024 | msn.comWhy Did Epilepsy/Seizure Focused-Marinus Pharmaceuticals Stock Hit 52-Week Low On Monday?April 15, 2024 | investorplace.comWhy Are Stocks Up Today?April 15, 2024 | investorplace.comWhy Is Marinus Pharmaceuticals (MRNS) Stock Down 79% Today?April 15, 2024 | marketwatch.comMarinus Pharmaceuticals' Trial of Therapy For Persistent Seizures Misses Early Stopping CriteriaApril 15, 2024 | businesswire.comMarinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial ResultsApril 9, 2024 | msn.comMarinus Pharmaceuticals Awards Stock Options to New Employees as InducementApril 5, 2024 | morningstar.comMarinus Pharmaceuticals Inc MRNSApril 5, 2024 | businesswire.comMarinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)March 27, 2024 | finance.yahoo.comMarinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant ReviewMarch 27, 2024 | businesswire.comMarinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus' Post Grant ReviewMarch 20, 2024 | finance.yahoo.comDo Options Traders Know Something About Marinus (MRNS) Stock We Don't?March 15, 2024 | ca.finance.yahoo.comMRNS Jul 2024 16.000 callSee More Headlines Receive MRNS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Marinus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/05/2024Today4/24/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MRNS CUSIPN/A CIK1267813 Webwww.marinuspharma.com Phone(484) 801-4670Fax203-315-0565Employees165Year FoundedN/APrice Target and Rating Average Stock Price Target$16.07 High Stock Price Target$28.00 Low Stock Price Target$3.00 Potential Upside/Downside+1,016.1%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-141,400,000.00 Net Margins-456.31% Pretax Margin-461.27% Return on Equity-269.75% Return on Assets-70.73% Debt Debt-to-Equity Ratio5.68 Current Ratio4.07 Quick Ratio4.01 Sales & Book Value Annual Sales$30.99 million Price / Sales2.55 Cash FlowN/A Price / Cash FlowN/A Book Value$0.31 per share Price / Book4.65Miscellaneous Outstanding Shares54,931,000Free Float51,932,000Market Cap$79.10 million OptionableOptionable Beta0.91 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Scott N. Braunstein M.D. (Age 61)CEO, President & Chairman Comp: $1.01MDr. Alex Aimetti Ph.D.Chief Scientific OfficerMs. Sonya WeigleSenior VP of Investor Relations, Human Resources & Corporate AffairsMs. Martha E. Manning Esq. (Age 69)J. D., Senior VP, General Counsel & Secretary Molly CameronDirector of Corporate Communications & Investor RelationsDr. Kimberly A. McCormick Pharm.D.Chief Regulatory & Quality Assurance OfficerMr. Thomas J. LyonsChief Business OfficerMr. David CzekaiSenior Vice President of Chemistry, Manufacturing & ControlsDr. Mark Paternoster Ph.D.Senior Vice President of DevelopmentDr. Dayong Li Ph.D.Senior Vice President of BiometricsMore ExecutivesKey CompetitorsOncolytics BiotechNASDAQ:ONCYInflaRxNASDAQ:IFRXAileron TherapeuticsNASDAQ:ALRNSpero TherapeuticsNASDAQ:SPROAffimedNASDAQ:AFMDView All CompetitorsInsiders & InstitutionsWellington Management Group LLPBought 85,455 shares on 3/5/2024Ownership: 0.442%Opaleye Management Inc.Sold 20,500 shares on 2/15/2024Ownership: 1.033%Superstring Capital Management LPBought 462,444 shares on 2/14/2024Ownership: 0.847%Campbell & CO Investment Adviser LLCBought 105,383 shares on 2/13/2024Ownership: 0.193%Alpha DNA Investment Management LLCSold 27,419 shares on 2/12/2024Ownership: 0.091%View All Insider TransactionsView All Institutional Transactions MRNS Stock Analysis - Frequently Asked Questions Should I buy or sell Marinus Pharmaceuticals stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Marinus Pharmaceuticals in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" MRNS shares. View MRNS analyst ratings or view top-rated stocks. What is Marinus Pharmaceuticals' stock price target for 2024? 7 Wall Street research analysts have issued twelve-month price targets for Marinus Pharmaceuticals' stock. Their MRNS share price targets range from $3.00 to $28.00. On average, they anticipate the company's share price to reach $16.07 in the next twelve months. This suggests a possible upside of 1,016.1% from the stock's current price. View analysts price targets for MRNS or view top-rated stocks among Wall Street analysts. How have MRNS shares performed in 2024? Marinus Pharmaceuticals' stock was trading at $10.87 at the start of the year. Since then, MRNS shares have decreased by 86.8% and is now trading at $1.44. View the best growth stocks for 2024 here. When is Marinus Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our MRNS earnings forecast. How were Marinus Pharmaceuticals' earnings last quarter? Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) announced its quarterly earnings results on Tuesday, March, 5th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.64) by $0.10. The biopharmaceutical company had revenue of $7.19 million for the quarter, compared to analyst estimates of $7.78 million. Marinus Pharmaceuticals had a negative net margin of 456.31% and a negative trailing twelve-month return on equity of 269.75%. During the same quarter in the prior year, the company posted ($0.76) earnings per share. What ETFs hold Marinus Pharmaceuticals' stock? ETFs with the largest weight of Marinus Pharmaceuticals (NASDAQ:MRNS) stock in their portfolio include Simplify Propel Opportunities ETF (SURI) and SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL). When did Marinus Pharmaceuticals' stock split? Marinus Pharmaceuticals shares reverse split on Wednesday, September 23rd 2020. The 1-4 reverse split was announced on Tuesday, September 22nd 2020. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 22nd 2020. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split. What other stocks do shareholders of Marinus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Marinus Pharmaceuticals investors own include Nordic American Tankers (NAT), The Gabelli Dividend & Income Trust (GDV), Sorrento Therapeutics (SRNE), Amarin (AMRN), Capricor Therapeutics (CAPR), Geron (GERN), Realty Income (O), Advanced Micro Devices (AMD), Novavax (NVAX) and Inovio Pharmaceuticals (INO). How do I buy shares of Marinus Pharmaceuticals? Shares of MRNS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MRNS) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe Greatest Bull Market in Crypto History…Weiss RatingsNew Trump BombshellThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Marinus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
